Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma

BACKGROUND: Researches on programmed cell death (PD-1) as neoadjuvant immunotherapy for resectable non-small cell lung cancer is underway, which brings hope for individuals with the disease. However, a study dedicated to lung squamous cell carcinoma (LUSC) specifically has yet to be conducted. Now,...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Dijian, Wang, Jiangfeng, Wu, Jie, Chen, Sheng, Li, Jianqiang, Liu, Jinshi, Chen, Qixun, Jiang, Youhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024839/
https://www.ncbi.nlm.nih.gov/pubmed/33841966
http://dx.doi.org/10.21037/jtd-21-103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024839/
https://www.ncbi.nlm.nih.gov/pubmed/33841966
http://dx.doi.org/10.21037/jtd-21-103

Ejemplares similares